Agreed on all counts. Still, this study is a start for ABBV's plan to move Imbruvica into earlier-stage indications, which is necessary to justify the colossal price of the PCYC deal.
Excellent detail. Most of these so called head to head comparisons, are really hand picked competition against a lesser opponent for obvious financial reasons.
Market Data 
Markets 
AI
